{"id":913819,"date":"2025-11-25T16:38:41","date_gmt":"2025-11-25T21:38:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/"},"modified":"2025-11-25T16:38:41","modified_gmt":"2025-11-25T21:38:41","slug":"lenz-therapeutics-to-present-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/","title":{"rendered":"LENZ Therapeutics to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Nov.  25, 2025  (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uEN2ZOsiv8b2MjM0rjbT-HTZyPoUkjJwRDXKFsL13-WcWoPfLat1ATJfMFW9eVHFRExIsa3EbeL-Ve7lDMBvwg==\" rel=\"nofollow\" target=\"_blank\">VIZZ\u2122<\/a> (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:<\/p>\n<p>\n        <strong>Piper Sandler 37<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Healthcare Conference <\/strong><br \/>\n        <br \/>\n        <strong>Date: <\/strong>December 2, 2025<br \/><strong>Location: <\/strong>New York City, NY<br \/><strong>Format: <\/strong>Fireside chat at 3:30pm ET (live audio\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vczm9Tt2-X8Eq2aJM108tK_pSqKq-8N3g0L3neJGbJrUp2etLNvKm8ZQt3nOWyDlw9U1UbmT6RKcfqrmKVH6UAyed0W2T8z-pFz_2WBN-eQmjxv-7FPbZcoWsmE3vtljLDSzaAhuLRaiTTLHXkyNCg==\" rel=\"nofollow\" target=\"_blank\">webcast<\/a>) and 1&#215;1 investor meetings<\/p>\n<p>\n        <strong>8<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Evercore Healthcare Conference<\/strong><br \/>\n        <br \/>\n        <strong>Date: <\/strong>December 3, 2025<br \/><strong>Location: <\/strong>Coral Gables, FL<br \/><strong>Format: <\/strong>Fireside chat at 1:20pm ET (live audio <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vczm9Tt2-X8Eq2aJM108tDCR34kzlHQPfQ4nTY9SbifvpkLzGLH3uepYFFRqJV3OnoJNCbPM5fb3hqi5dVsGr6LTInlMnpB1d3eCF_RgyC51oFO3dYUTpt28vJK8Qur3\" rel=\"nofollow\" target=\"_blank\">webcast<\/a>) and 1&#215;1 investor meetings<\/p>\n<p>\n        <strong>Citi\u2019s 2025 Global Healthcare Conference<\/strong><br \/>\n        <br \/>\n        <strong>Date: <\/strong>December 4, 2025<br \/><strong>Location: <\/strong>Miami, FL<br \/><strong>Format: <\/strong>Fireside chat at 10:30am ET (live audio <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vczm9Tt2-X8Eq2aJM108tFkacVNdtBndl5gMrAuYCL2h3bFyHpJqmc5kpxBL-tk7LxcbmExW-ckTbZCEW0xxt50FJFt2J_hXo0G2wuzVxFqkaezwt_f1L6mJIQjmNjmB4O4DxiMhE6cvn8OudX2XmDU5XdWElLFVV_AalsUtNAQ=\" rel=\"nofollow\" target=\"_blank\">webcast<\/a>) and 1&#215;1 investor meetings<\/p>\n<p align=\"justify\">Live audio webcasts will also be available on the LENZ Therapeutics website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M3dRL35a_80qYKi9ei2KP7k625J9ANFl8QAHfDim6LBufEdKgnEUwcw0CrHuKsw24fH95yEcR5159i3ZHkPPqw==\" rel=\"nofollow\" target=\"_blank\">www.LENZ-tx.com<\/a> in the Investors &amp; Media section. A replay of the webcasts will be available on the Company\u2019s website for 12 months following the event.<\/p>\n<p align=\"justify\">\n        <strong>About LENZ Therapeutics<\/strong><br \/>\n        <br \/>LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ<sup>TM<\/sup> (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hpeXdGrZtxW7qRxYOdyR9Yr8RvxV3ngzarP7jnQ5eUZM5vaGTA5p829B8jqw4nvkwL5IpKZuYeeFqgMN_Uvj-A==\" rel=\"nofollow\" target=\"_blank\">www.VIZZ.com<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M3dRL35a_80qYKi9ei2KP-lE3nrDzMK23j6zowYkd3mZvijnYPuW6MCaN_vWe29iDzPkkpH5N3QgQB819niQfw==\" rel=\"nofollow\" target=\"_blank\">www.LENZ-tx.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Dan Chevallard <br \/>LENZ Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zBPIdHry2xGiuW3-eFDx9tql4rn6G3y_Hsnb6z18YsKEu4uLsc9NGna3bol0NnTe6StM6T2bqnETy1JAvE08hQ==\" rel=\"nofollow\" target=\"_blank\">IR@LENZ-Tx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjNkMjlmZmYtZWJmOS00OTkyLWIyOGItOTZmMmIxNWRkMTAzLTEyNzU1MzctMjAyNS0xMS0yNS1lbg==\/tiny\/LENZ-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u2122 (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: Piper Sandler 37 th Annual Healthcare Conference Date: December 2, 2025Location: New York City, NYFormat: Fireside chat at 3:30pm ET (live audio\u00a0webcast) and 1&#215;1 investor meetings 8 th Annual Evercore Healthcare Conference Date: December 3, 2025Location: Coral Gables, FLFormat: Fireside chat at 1:20pm ET (live audio webcast) and 1&#215;1 investor meetings Citi\u2019s 2025 Global Healthcare Conference Date: December 4, 2025Location: Miami, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LENZ Therapeutics to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-913819","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LENZ Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LENZ Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u2122 (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: Piper Sandler 37 th Annual Healthcare Conference Date: December 2, 2025Location: New York City, NYFormat: Fireside chat at 3:30pm ET (live audio\u00a0webcast) and 1&#215;1 investor meetings 8 th Annual Evercore Healthcare Conference Date: December 3, 2025Location: Coral Gables, FLFormat: Fireside chat at 1:20pm ET (live audio webcast) and 1&#215;1 investor meetings Citi\u2019s 2025 Global Healthcare Conference Date: December 4, 2025Location: Miami, &hellip; Continue reading &quot;LENZ Therapeutics to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T21:38:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LENZ Therapeutics to Present at Upcoming Investor Conferences\",\"datePublished\":\"2025-11-25T21:38:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"},\"wordCount\":270,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/\",\"name\":\"LENZ Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc=\",\"datePublished\":\"2025-11-25T21:38:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LENZ Therapeutics to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LENZ Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"LENZ Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u2122 (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: Piper Sandler 37 th Annual Healthcare Conference Date: December 2, 2025Location: New York City, NYFormat: Fireside chat at 3:30pm ET (live audio\u00a0webcast) and 1&#215;1 investor meetings 8 th Annual Evercore Healthcare Conference Date: December 3, 2025Location: Coral Gables, FLFormat: Fireside chat at 1:20pm ET (live audio webcast) and 1&#215;1 investor meetings Citi\u2019s 2025 Global Healthcare Conference Date: December 4, 2025Location: Miami, &hellip; Continue reading \"LENZ Therapeutics to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-25T21:38:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LENZ Therapeutics to Present at Upcoming Investor Conferences","datePublished":"2025-11-25T21:38:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/"},"wordCount":270,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/","name":"LENZ Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc=","datePublished":"2025-11-25T21:38:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjMxMyM3MjkyODM2IzIyNjM5ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LENZ Therapeutics to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=913819"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913819\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=913819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=913819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=913819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}